Short Communication
Volume 14:02, 2024

Medicinal Chemistry

ISSN: 2161-0444 Open Access

Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-positive Breast Cancer

Belisario Ander*
Department of Clinical Pharmacy, Universiti Teknologi MARA, Puncak Alam 42300, Selangor, Malaysia

Introduction

Breast cancer remains one of the most prevalent malignancies among women globally, with estrogen receptor-positive (ER+) breast cancer representing a significant subset. Despite advancements in detection and treatment modalities, advanced or metastatic ER+ breast cancer continues to pose therapeutic challenges due to tumor heterogeneity, acquired resistance and metastatic spread. However, recent years have witnessed significant progress in understanding the molecular mechanisms underlying ER+ breast cancer, leading to the development of novel targeted therapies and treatment strategies. This article aims to explore the current landscape of therapies for advanced/metastatic ER+ breast cancer, focusing on hormonal therapies, targeted therapies and emerging treatment modalities [1].

Description

Hormonal therapies

Hormonal therapies have been the cornerstone of treatment for ER+ breast cancer owing to the dependency of these tumors on estrogen signaling for growth and survival. Selective estrogen receptor modulators (SERMs) such as tamoxifen and selective estrogen receptor degraders (SERDs) like fulvestrant are standard first-line options for hormone receptor-positive breast cancer [2].

Tamoxifen: Tamoxifen, a first-generation SERM, competitively binds to the estrogen receptor, thereby inhibiting estrogen-mediated tumor growth. Despite being widely used for decades, its efficacy can be limited by acquired resistance and adverse effects such as thromboembolic events and endometrial cancer.

Fulvestrant: Fulvestrant, a selective estrogen receptor down-regulator, exerts its antitumor effects by targeting the estrogen receptor for degradation. It has shown efficacy both as first-line and subsequent-line therapy in advanced ER+ breast cancer, particularly in postmenopausal women. However, its clinical utility may be limited by the need for intramuscular administration and associated injection site reactions [3].

AIs, including letrozole, anastrozole and exemestane, inhibit the conversion of androgens to estrogens in postmenopausal women, thereby reducing estrogen levels. AIs are commonly used either as first-line therapy or sequentially following tamoxifen treatment. However, resistance to AIs can develop over time, prompting the exploration of novel treatment strategies.

Targeted therapies

In addition to hormonal therapies, targeted agents that specifically inhibit key signaling pathways implicated in ER+ breast cancer have emerged as valuable treatment options.

CDK4/6 inhibitors: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, ribociclib and abemaciclib, have revolutionized the management of advanced ER+ breast cancer. By inhibiting the CDK4/6 pathway, these agents suppress cell cycle progression and enhance the efficacy of hormonal therapies. CDK4/6 inhibitors have demonstrated significant improvements in progression-free survival when combined with aromatase inhibitors or fulvestrant in both first-line and subsequent-line settings. Common adverse effects include hematologic toxicity and fatigue [4].

Pi3k inhibitors: The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway is frequently dysregulated in ER+ breast cancer, making it an attractive target for therapy. PI3K inhibitors such as alpelisib have shown promise in combination with endocrine therapy, particularly in tumors harboring PIK3CA mutations. However, their clinical utility may be limited by toxicities such as hyperglycemia and dermatologic adverse events.

Her2-targeted therapies: While ER+ breast cancers are typically HER2-negative, a subset may exhibit HER2 amplification or overexpression, warranting the use of HER2-targeted therapies such as trastuzumab and pertuzumab in combination with hormonal therapies.

Emerging treatment modalities

Recent advances in cancer research have paved the way for novel treatment modalities that hold promise for the management of advanced ER+ breast cancer.

Immunotherapy: While immunotherapy has demonstrated remarkable efficacy in various malignancies, its role in ER+ breast cancer remains under investigation. Strategies such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy are being explored either as monotherapy or in combination with hormonal and targeted therapies to enhance antitumor immune responses [5].

Precision medicine: The advent of next-generation sequencing technologies has enabled the identification of actionable genetic alterations in ER+ breast cancer, allowing for personalized treatment approaches. Precision medicine initiatives aim to match patients with targeted therapies based on the molecular profile of their tumors, thereby optimizing treatment outcomes and minimizing unnecessary toxicities.

Conclusion

Advanced/metastatic ER+ breast cancer presents a complex clinical challenge necessitating a multimodal treatment approach. Hormonal therapies remain the cornerstone of management, supplemented by targeted agents that exploit key signaling pathways dysregulated in ER+ breast cancer. Recent advancements in precision medicine and immunotherapy offer new avenues for therapeutic intervention, with the potential to further improve patient outcomes. However, ongoing research is needed to elucidate optimal treatment sequencing, overcome resistance mechanisms and identify biomarkers predictive of treatment response. Collaborative efforts between

***Address for Correspondence:** Belisario Ander, Department of Clinical Pharmacy, Universiti Teknologi MARA, Puncak Alam 42300, Selangor, Malaysia; E-mail: ander.belisario@unikl.edu.my*

Received: 26 March 2024, Manuscript No. mccr-24-136052; **Editor Assigned:** 29 March, 2024, PreQC No. P-136052; **Reviewed**: 13 April, 2024, QC No. Q-136052; **Revised**: 20 April, 2024, Manuscript No. R-136052; **Published**: 27 April, 2024, DOI: 10.37421/2161-0444.2024.14.725

clinicians, researchers and pharmaceutical companies are essential to drive innovation and enhance the arsenal of therapies available for this devastating disease.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Chen, Yajun, Yuyu Qiu, Wangbingfei Chen and Qufu Wei. "Electrospun thymol-loaded porous cellulose acetate fibers with potential biomedical applications." *Mater Sci Eng C* 109 (2020): 110536.
2. Ma, Si-Yuan, Ling-Gao Shi, Zheng-Bing Gu and Yu-Lan Wu, et al. "Two new chromone glycosides from the roots of Saposhnikovia divaricata." *Chem Biodivers* 15 (2018): e1800253.
3. Park, Soo-Jin, Hwa-Jeong Hahn, Sei-Ryang Oh and Hyun-Jun Lee, et al. "Theophylline Attenuates BLM-Induced Pulmonary Fibrosis by Inhibiting Th17 Differentiation." *Int J Mol Sci* 24 (2023): 1019.
4. Liu, Zi, Liang Ma, Zhe-Sheng Wen and Yong-Xian Cheng, et al. "Ethoxysanguinarine induces inhibitory effects and downregulates CIP2A in lung cancer cells." *ACS Med Chem Lett* 5 (2014): 113-118.
5. Khanna, Anchit, Juha Okkeri, Turker Bilgen and Timo Tiirikka, et al. "ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells." *PloS One* 6 (2011): e17979.

How to cite this article: Ander, Belisario. "Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-positive Breast Cancer." *Med Chem* 14 (2024): 725.